

World Journal of Advanced Engineering Technology and Sciences

eISSN: 2582-8266 Cross Ref DOI: 10.30574/wjaets Journal homepage: https://wjaets.com/



(REVIEW ARTICLE)

Check for updates

Artificial intelligence and machine learning for early cancer prediction and response

AnandKumar Chennupati *

Masters in Computer Applications, Jawaharlal Nehru Technological University, Hyderabad, Ashok Nagar, India.

World Journal of Advanced Engineering Technology and Sciences, 2024, 12(01), 035–040

Publication history: Received on 30 March 2024; revised on 05 May 2024; accepted on 07 May 2024

Article DOI: https://doi.org/10.30574/wjaets.2024.12.1.0178

Abstract

Worldwide, cancer claims more lives than any other disease. Although cancer detection, prognosis, and treatment have all advanced, one major obstacle is the lack of personalized, data-driven care. Artificial intelligence (AI), used to forecast and automate numerous malignancies, has emerged as a viable solution for increasing healthcare accuracy and patient outcomes. Artificial intelligence applications in cancer include risk evaluation, early detection, patient prognosis prediction, and treatment selection based on comprehensive data. Machine learning (ML), a form of artificial intelligence that allows computers to learn from training data, is very successful in predicting breast, brain, lung, liver, and prostate cancers. Indeed, AI and machine learning have outperformed physicians in predicting cancer. These technologies can potentially enhance the diagnosis, prediction, and quality of life of patients with a wide range of disorders, not just cancer. As a result, it is critical to enhance existing AI and ML technologies and create new programs to help patients. This article discusses the use of AI and machine learning algorithms in cancer prediction, including its present uses, future possibilities, and limitations.

Keywords: Artificial Intelligence; Machine Learning; Cancer Prediction; Early Diagnosis; Deep Learning; Cancer Prevention

1. Introduction

Cancer remains one of the most challenging issues in contemporary medicine, claiming millions of lives each year. Despite substantial breakthroughs in treatment techniques, early identification and quick action are the keys to minimizing death rates. Cancer is a significant public health concern worldwide, with an increased incidence and fatality rate. According to the GLOBOCAN 2020 database, roughly 19.3 million new cases and 10 million fatalities are recorded yearly. Lung cancer is the leading cause of cancer-related mortality, with an estimated 1.8 million deaths, followed by stomach, liver, colorectal, and breast cancer. Cancer prevention and therapy remain tough. Cancer is the second largest cause of mortality in the United States, after only heart disease. In 2023, the US is expected to have 1.9 million new cancer cases (equal to about 5370 cases per day) and 609,820 cancer-related fatalities (similar to approximately 1670 deaths per day). According to the "Global Cancer Observatory" data, 37 people are diagnosed with cancer each minute, and more than 19 people succumb to the illness.

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

^{*} Corresponding author: AnandKumar Chennupati.



Figure 1 (A). The estimated number of new cases globally in 2020 for both sexes. (B) The estimated number of deaths globally in 2020 for both sexes.

Machine learning and artificial intelligence enhance cancer prevention and management. Artificial intelligence is a collection of computer-coded programs or algorithms that use data analysis and pre-programmed instructions to forecast and judge different aspects of an illness. Machine learning is a subfield of artificial intelligence that refers to a collection of algorithms that learn and improve automatically based on experience. In other words, machine learning is a subset of artificial intelligence that focuses on creating algorithms that can learn from data and improve their performance over time. Deep learning is a branch of "machine learning" that uses neural network-based models to mimic the human brain's ability to analyze massive volumes of complex data in fields including language processing, drug discovery, and picture identification.



Figure 2 An overview of Artificial Intelligence, Machine Learning and Deep Learning.

These algorithms gather information from various sources, such as imaging studies, medical records, and investigations, to detect or predict the onset of cancer. Modern surgical procedures can now detect and diagnose brain cancers in realtime, thanks to advancements in imaging technology and artificial intelligence (AI). This approach accurately detected cancerous tissue, revealing an impressive ability to differentiate between normal and malignant tissue. By utilizing artificial intelligence (AI) to examine gene expression patterns, researchers accurately categorized cancers according to their activity levels, distinguishing between active, hyperactive, and quiet genes in both cancerous and healthy tissue. Similarly, researchers have used machine learning methods to detect mismatch repair deficits (dMMR) in colorectal screening. Liver cancer rehabilitation groups have tested AI approaches like CS-SVM, demonstrating their ability to predict the date and location of cancer recurrence. According to studies, various ML and AI techniques serve as models for global practices, allowing cancer researchers to revolutionize medicine by performing multifaceted tasks to improve clinical workflow and diagnostic accuracy, reduce human resource costs, increase data efficiency, and improve treatment. As a result, academics are increasingly addressing the use of AI and machine learning for cancer prediction, diagnosis, and rehabilitation; evaluating the broad reach, progress, and successes may serve as a standard for future studies and applications of ground-breaking technology.

Despite the rapid integration of AI into cancer research, artificial intelligence-based therapies are still in their early stages. Pharmaceutical companies, hospitals, and other entities have approved only a few AI-based applications for real-world use. Whether artificial intelligence can replace medical practitioners as professionals is still being determined.

Much public discussion about artificial intelligence focuses on its application in cancer clinical research. As a result, research into AI technology has grown, with performance comparable to human biological specialists. Furthermore, AI will provide more information to human decision-makers and may become an essential component of the healthcare team. This article provides an overview of AI and ML in cancer clinical research, covering prediction and response.

1.1. Machine Learning

Scholars define ML as an academic discipline that combines computer science, statistics, and mathematics. Machine learning drives the growth of artificial intelligence. Machine learning can identify patterns in data and extract information from them to make predictions. Generally, machine learning models and algorithms gain knowledge through experience. These models and methods extract patterns from data and associate them with compact classes of samples. For instance, an ML model with experience, given a set of features describing a person, can predict whether the person is ill or healthy; given a set of parameters describing an animal, it can predict whether the animal is receiving treatment or not; and given a set of features describing molecules, it can indicate whether the molecules are likely to interact or not. ML algorithms can also identify such patterns in an agnostic manner, meaning they do not require knowledge of the classes. These strategies are known as supervised and unsupervised machine learning, respectively. Reinforcement learning is a third kind of machine learning that seeks a sequence of activities contributing to achieving

a specific goal. These approaches are becoming more popular in biomedical research, including treatment outcome prediction, drug development, medical imaging analysis, patient stratification, molecular interactions, and many others.

1.2. The Use of Artificial Intelligence in Healthcare

Artificial intelligence (AI) in medical care refers to the use of software or "machine-learning algorithms" to duplicate human "cognition" in the inspection, presentation, and interpretation of complicated health and medical data. Artificial intelligence, in particular, has the potential to generate results based only on incoming data. The primary purpose of AI applications in healthcare is to examine the relationship between patient outcomes and therapeutic interventions. Artificial intelligence's ability to collect, analyze, interpret, and produce a specified output is what separates artificial intelligence from previous methodologies. AI accomplishes this by utilizing deep learning and machine learning algorithms. These systems may identify behavioral patterns and generate their reasoning. Diagnostic procedures, pharmaceutical development, customized medicine, patient monitoring, and treatment protocol design utilize AI-based information. For instance, it accurately identifies and stratifies individuals with "coronary artery disease." Artificial intelligence algorithms have shown potential as an early intervention tool for accurately diagnosing coronary artery disease.

Several sectors of gastroenterology also use artificial intelligence. Endoscopic procedures, such as colonoscopies and esophagogastroduodenoscopies, rely on the early identification of abnormal tissue. Researchers now anticipate that using AI in these endoscopic procedures will help practitioners diagnose diseases, evaluate their severity, and discover blind spots more quickly.

1.3. Applications of Machine Learning in Cancer Prediction

The capacity to reliably forecast which treatment regimens are most suited for each patient based on their unique genomic, genetic, and tumor-based characteristics is a difficult challenge in oncologic care that AI is designed to address. Much research has examined the uses of AI in cancer risk assessment, diagnostics, cancer medicine development, and genetic tumor characterization to determine whether AI and its subfields, including machine learning, can aid in oncology treatment. According to these findings, ML may aid in cancer prediction and diagnosis by studying pathology profiles, imaging investigations, and the capacity to transform images into "mathematical sequences." In January 2020, researchers created an artificial intelligence system based on the "Google DeepMind algorithm" that outperformed human "breast cancer" detection professionals. In July 2020, the University of Pittsburgh created an AI system-based machine learning approach with the most fantastic accuracy in identifying prostate cancer, with a specificity of 98% and a sensitivity of 98%. Recent research employed an upgraded ViT (Vision Transformer) architecture, ViT-Patch, and validated it using a publicly accessible dataset. The study results demonstrate that it is effective for malignant identification and tumor localization.

A study used machine learning methods to identify cancer-related data and provide a breast cancer diagnosis. To make a robust model for predicting breast cancer, an observational study looked at how well the support vector machine, artificial neural networks (ANN), Naive Bayes classifier, and AdaBoost tree worked. We used principal component analysis to minimize dimensionality. The research discovered that unlike other approaches, such as decision trees and regression trees, artificial neural networks (ANN) were the most popular.

The ANN technique provided a viable way to make real-time forecasts and prognoses. Pulse-coupled Neural networks have been used in the field for image processing. A study looked at the downsides and benefits of different neural network architectures. According to the survey, multilayer auto-encoders, probabilistic models, and neural networks achieved 96% accuracy on a cancer dataset. The study used the Wisconsin Diagnostic Breast Cancer dataset to test many machine learning approaches, including support vector machines, linear regression, multilayer perceptron, and SoftMax regression. The findings showed that all the machine language algorithms effectively completed the classification task and had high test accuracy in cancer prediction. This research also indicated that more precise feature selection strategies, as applied in the proposed model, may improve prediction accuracy.

1.4. Application of AI in Cancer Prediction

Researchers have shown that artificial intelligence algorithms can evaluate unstructured data and accurately forecast the chance of individuals developing various ailments, including cancer. Caregivers of all levels, from specialists to paramedics, have faced the challenge of anticipating cancer prognoses based on their professional expertise over the last several decades. As the digital data age emerges, clinicians see the need to use AI advancements such as DL and ML. They argue that the complexity and scope of statistical analysis make it impossible to predict how cancer will grow. Healthcare professionals are also worried about the possibility that a patient would catch an illness, have a tumor

recurrence after treatment, or die. These factors have a significant impact on treatment choices and outcomes. Most clinical cancer research focuses on predicting patient responses to treatment or establishing prognosis. Patients with more precise prognoses may benefit from more effective medicines; these treatment choices often entail personalized or individualized care for each patient. AI can review and comprehend "multi-factor" data from several patient evaluations to predict cancer, providing more accurate information regarding patient survival, prognosis, and disease progression forecasts.

The entire population could potentially benefit from these AI algorithms. These algorithms may help patients who are at high risk of getting cancer or who do not meet the conventional screening requirements. Although standard screening approaches for those with "early-onset sporadic colorectal cancer" are limited, patients may benefit from tight risk-based screening recommendations.

Individualized risk prediction may aid in early detection and possibly boost treatment rates for cancers that do not have an established screening approach and are primarily asymptomatic in the early stages. For example, an "artificial neural network model" for forecasting "pancreatic cancer" risk achieved an area under the "receiver operating characteristic curve" of 85%. In low-resource contexts, personalized risk calculation algorithms may help prioritize "screening for high-risk" individuals.

1.5. Limitations

Quality and Quantity of Data: AI systems need a substantial quantity of high-quality data to learn properly. However, in the medical industry, obtaining such data might be difficult owing to privacy issues, data silos, and heterogeneity in data-gathering techniques. Limited or biased datasets might result in erroneous predictions and impede the performance of AI algorithms. Clarity and Transparency: People sometimes refer to most artificial intelligence systems, especially deep learning algorithms, as "black boxes," implying that their decision-making processes are difficult for humans to understand. In healthcare, where choices may have life-changing repercussions, practitioners must comprehend the reasoning behind AI-powered suggestions. Lack of openness may cause distrust and reluctance to use AI technology.

Bias and Generalization: AI models developed for certain populations or datasets may fail to generalize across varied patient demographics or healthcare environments. This may lead to biased forecasts or recommendations that disproportionately harm certain populations. For example, if a model is trained exclusively on data from a single ethnicity, it may underperform when applied to patients from other ethnicities, resulting in discrepancies in healthcare results.

Regulatory and Ethical Issues: The use of AI in healthcare involves numerous regulatory and ethical concerns. Regulatory organizations face the challenge of adapting current frameworks to integrate rapidly expanding AI technology, all while ensuring patient safety and privacy. Furthermore, ethical quandaries emerge about data privacy, patient permission, and the possibility of AI supplanting human judgment in healthcare decision-making. Achieving a balance between innovation and regulation is critical for maximizing the advantages of AI in cancer treatment while reducing possible hazards.

1.6. Future Possibilities

AI algorithms have the potential to significantly improve diagnosis accuracy by evaluating complex patterns in medical imaging, biomarkers, and genetic data. This could lead to an early diagnosis of malignant tumors and fewer false-positive and false-negative outcomes. AI-powered models show promise for personalizing treatment regimens for individual patients based on their genetic profiles, tumor features, and medical histories. Customized medicine can enhance effectiveness and prevent unwanted effects by anticipating therapy responses and discovering appropriate therapeutic techniques.

In the future, we expect to use AI-powered real-time monitoring and intervention systems in cancer treatment. These devices would continually evaluate patient data, such as biomarker levels and vital signs, allowing for the early diagnosis of cancer recurrence or treatment-related problems. Implementing timely interventions and modifications to treatment regimens could improve patient outcomes and reduce healthcare expenditures. AI can transform the drug development process by speeding up the identification of prospective therapeutic candidates based on molecular structures and biochemical interactions. This might lead to more focused medicines with excellent success rates and fewer side effects.

Moreover, improvements in wearable technology and telemedicine platforms will make integrating AI-powered cancer diagnosis and monitoring technologies into daily life easier. Patients can undertake remote screenings, get real-time

feedback on their health condition, and interact with healthcare experts without visiting a healthcare facility physically. AI will also benefit collaborative research endeavors by allowing for the integration and analysis of large-scale datasets from various sources. Researchers can speed up discoveries, test AI models, and enhance the generalizability of results across populations and healthcare settings by breaking down data silos and promoting data-sharing programs.

Rather than displacing healthcare experts, AI has the potential to strengthen them by giving them decision-support tools, automating mundane activities, and synthesizing large quantities of medical literature. This enables doctors to concentrate on patient care, make joint decisions, and use AI insights to enhance treatment regimens and improve patient outcomes. In summary, the future of AI and machine learning in early cancer detection and response has enormous potential to transform healthcare delivery, empower people, and, ultimately, save lives. Continued investment in research, innovation, and cooperation is required to realize the full potential of these transformational technologies in the battle against cancer.

2. Conclusion

We have shown that applying AI and ML to healthcare data has the potential to transform early cancer prediction while also providing help for capacity problems via automation. AI and machine learning can analyze complicated data across several modalities. These groundbreaking discoveries were previously restricted to non-medical purposes, but they are now finding their way into healthcare systems throughout the globe. AI and machine learning have already greatly influenced the healthcare industry and will continue to do so. Oncology has enormous untapped potential that could revolutionize cancer detection, prognosis, and therapy, among many other areas of cancer research.

Early diagnosis, prediction, and response are crucial for cancer prevention since it is one of the most deadly diseases. This article discusses recent developments in machine learning, artificial intelligence, and deep learning. Combining DL, ML, and AI into various cancer diagnostic and prediction technologies could potentially enhance the success of cancer therapy in the future. This might benefit hospitals that treat multiple conditions, not just cancer. These ever-improving algorithms will surely help us conquer the challenges posed by this dreadful illness. More research is necessary to establish analytical and clinical validity and therapeutic utility with these goals in mind.

References

- [1] Hunter B, Hindocha S, Lee RW. The Role of Artificial Intelligence in Early Cancer Diagnosis. *Cancers*. 2022; 14(6):1524.
- [2] Zhang, B., Shi, H., & Wang, H. (2023). Machine Learning and AI in Cancer Prognosis, Prediction, and Treatment Selection: A Critical Approach. *Journal of Multidisciplinary Healthcare*, *16*, 1779–1791.
- [3] Ahmad M, Khan Z, Rahman ZU, Khattak SI, Khan ZU. Can innovation shocks determine CO2 emissions (CO2e) in the OECD economies? A new perspective. *Econ Innov New Technol*. 2021;<u>30(1)</u>:89–109.
- [4] Gaur K, Jagtap MM. Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. *Cureus*. 2022;14(11).
- [5] World Health Organization. © International Agency for Research on Cancer, 2020. Cancer Today.
- [6] Gaur K, Jagtap MM. Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. *Cureus*. 2022;14(11). doi:10.7759/cureus.31008
- [7] Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. 61–71.
- [8] Vaishya R, Javaid M, Khan IH, Haleem A. Artificial Intelligence (AI) applications for COVID-19 pandemic. *Diabetes Metab Syndr*. 2020;<u>14(4)</u>:337–339.
- [9] Cao J-S, Z-Y L, Chen M-Y, et al. Artificial intelligence in gastroenterology and hepatology: status and challenges. *World J Gastroenterol*. 2021;27(16):1664.
- [10] Afolabi LO, Afolabi MO, Sani MM, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. *Clinical Translat Immunol*. 2021;10(6): e1286.
- [11] *Cancer Today.* (n.d.).https://gco.iarc.fr/today/online-analysispie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex =0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group %5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0.